From the Washington Business Journal:
Gaithersburg biotech MedImmune and Boston-based Joslin Diabetes Center announced plans Tuesday to work together on new drug candidates that could someday regenerate insulin cells, increase calorie-burning“brown fat” or even replicate the effects of bariatric surgery.
It’s like you can almost feel it in the air that something amazing is happening in diabetes research. At last weekend’s JDRF TypeOneNation Research Summit in Maryland, JDRF Board Chairman John Brady discussed a Janssen Research and Development Inc-JDRF effort to “intercept” Type 1 diabetes.
Not to get my hopes up, but all this effort has to lead somewhere.